|Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy|
GM Clifford, J Polesel, M Rickenbach, L Dal Maso, O Keiser, A Kofler, ...
Journal of the National Cancer Institute 97 (6), 425-432, 2005
|Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study|
S Stringhini, A Wisniak, G Piumatti, AS Azman, SA Lauer, H Baysson, ...
The Lancet 396 (10247), 313-319, 2020
|Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients|
M Rotger, S Colombo, H Furrer, G Bleiber, T Buclin, BL Lee, O Keiser, ...
Pharmacogenetics and genomics 15 (1), 1-5, 2005
|Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies|
LF Johnson, J Mossong, RE Dorrington, M Schomaker, CJ Hoffmann, ...
PLoS medicine 10 (4), e1001418, 2013
|Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries|
MWG Brinkhof, F Dabis, L Myer, DR Bangsberg, A Boulle, D Nash, ...
Bulletin of the World Health Organization 86, 559-567, 2008
|Retention in care under universal antiretroviral therapy for HIV infected pregnant and breastfeeding women (“Option B+”) in Malawi|
L Tenthani, AD Haas, H Tweya, A Jahn, JJ Van Oosterhout, ...
AIDS (London, England) 28 (4), 589, 2014
|Changing patterns of cancer incidence in the early-and late-HAART periods: the Swiss HIV Cohort Study|
S Franceschi, M Lise, GM Clifford, M Rickenbach, F Levi, M Maspoli, ...
British journal of cancer 103 (3), 416-422, 2010
|Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub‐Saharan Africa: systematic review and meta‐analysis|
C Mugglin, J Estill, G Wandeler, N Bender, M Egger, T Gsponer, O Keiser, ...
Tropical Medicine & International Health 17 (12), 1509-1520, 2012
|Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes|
M May, A Boulle, S Phiri, E Messou, L Myer, R Wood, O Keiser, ...
The Lancet 376 (9739), 449-457, 2010
|Long-term immunologic response to antiretroviral therapy in low-income countries: Collaborative analysis of prospective studies: The Antiretroviral Therapy in Lower Income …|
D Nash, M Katyal, MWG Brinkhof, O Keiser, M May, R Hughes, F Dabis, ...
AIDS (London, England) 22 (17), 2291, 2008
|Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients|
A Muzzi, G Leandro, L Rubbia-Brandt, R James, O Keiser, R Malinverni, ...
Journal of hepatology 42 (1), 41-46, 2005
|Electronic medical record systems, data quality and loss to follow-up: survey of antiretroviral therapy programmes in resource-limited settings|
M Forster, C Bailey, MWG Brinkhof, C Graber, A Boulle, M Spohr, ...
Bulletin of the World Health Organization 86, 939-947, 2008
|Missed opportunities to prevent mother-to-child-transmission in sub-Saharan Africa: systematic review and meta-analysis|
C Wettstein, C Mugglin, M Egger, N Blaser, L Salazar, J Estill, N Bender, ...
AIDS (London, England) 26 (18), 2361, 2012
|Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring|
O Keiser, H Tweya, A Boulle, P Braitstein, M Schechter, MWG Brinkhof, ...
AIDS (London, England) 23 (14), 1867, 2009
|Public-health and individual approaches to antiretroviral therapy: township South Africa and Switzerland compared|
O Keiser, C Orrell, M Egger, R Wood, MWG Brinkhof, H Furrer, ...
PLoS medicine 5 (7), e148, 2008
|Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study|
AD Haas, L Tenthani, MT Msukwa, K Tal, A Jahn, OJ Gadabu, A Spoerri, ...
The lancet HIV 3 (4), e175-e182, 2016
|Outcomes of the South African national antiretroviral treatment programme for children: the IeDEA Southern Africa collaboration|
MA Davies, O Keiser, B Eley, H Rabie, G van Cutsem, J Giddy, R Wood, ...
South African medical journal 99 (10), 2009
|Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa|
MP Fox, G Van Cutsem, J Giddy, M Maskew, O Keiser, H Prozesky, ...
Journal of acquired immune deficiency syndromes (1999) 60 (4), 428, 2012
|Immunodeficiency at the start of combination antiretroviral therapy in low-, middle-and high-income countries|
Journal of acquired immune deficiency syndromes (1999) 65 (1), e8, 2014
|Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland|
J Perez-Saez, SA Lauer, L Kaiser, S Regard, E Delaporte, I Guessous, ...
The Lancet Infectious Diseases 21 (4), e69-e70, 2021